Abstract
Background: Attempts to prolong life with antiarrhythmic drugs in patients at increased risk of sudden cardiac death have so far been disappointing or inconclusive.
Hypothesis: The Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) encompass two survival studies testing the prophylactic use of the selective potassium‐channel blocker, dofetilide, in patients at high risk of sudden death.
Methods: The first study includes patients admitted to hospital with congestive heart failure (CHF), the other includes patients with acute myocardial infarction (MI) within the previous 7 days. In both studies patients must have left ventricular systolic dysfunction (ejection fraction 35%) determined by echocardiography. Each of the two studies are planned to enroll 1500 patients. Consecutive hospitalized patients with MI or CHF are screened in 37 Danish hospitals. Eligible patients are randomized to receive dofetilide or matching placebo. All patients are continuously monitored by telemetry for the first 3 days of the study to detect possible arrhythmic events and to ensure resuscitation in case of serious arrhythmias. Minimum duration of follow‐up is 12 months.
Results: Between November 1993 and July 1996, a total of 5812 consecutive patients with CHF and 8688 consecutive patients with MI was screened for entry. Of these, 1518 patients were included in the CHF study and 1510 patients in the MI study. Overall 1‐year mortality of randomized patients were 28 and 22%, respectively.
Conclusion: DIAMOND will provide important data on the safety and efficacy of dofetilide in high‐risk patients with left ventricular dysfunction and either CHF or MI, as well as evaluate tolerability in these populations.
Keywords: congestive heart failure, myocardial infarction, left ventricular dysfunction, prognosis, dofetilide
Full Text
The Full Text of this article is available as a PDF (721.6 KB).
References
- 1. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias‐Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene L, Huther L, Richardson DW, and the CAST Investigators : Mortality and morbidity in patients receiving encainide, flecainide or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781–788 [DOI] [PubMed] [Google Scholar]
- 2. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP: Effect of d‐sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d‐Sotalol. Lancet 1996. Jul 6 1996; 348: 7–12 [DOI] [PubMed] [Google Scholar]
- 3. Doval HC, Nul DR, Perrone SV, Bortman GR, Curiel R, for Grupo de Estudio de la Sobrevida en la Insufficiencia en Argentina (GESICA) : Randomized trial of low dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493–498 [DOI] [PubMed] [Google Scholar]
- 4. Nicklas JM, McKenna WJ, Stewart RA, Mickelson JK, Das SK, Schork MA, Krikler SJ, Quain LA, Moradi F, Pitt B: Prospective, double blind controlled trial of low dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J 1991; 122: 1016–1021 [DOI] [PubMed] [Google Scholar]
- 5. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, Lazzeri D: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (see comments). N Engl J Med 1995; 333: 77–82 [DOI] [PubMed] [Google Scholar]
- 6. Julian D, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz P, Simon P, The European Myocardial Infarct Amiodarone Trial Investigators : Randomised trial of effect of amiodarone on mortality in patients with left‐ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667–674 [DOI] [PubMed] [Google Scholar]
- 7. Cairns JA, Conolly SJ, Roberts R, Gent M, The Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators : Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349: 675–682 [DOI] [PubMed] [Google Scholar]
- 8. Gwilt M, Arrowsmith JE, Blackburn KJ, Burges RA, Cross PE, Dalrymple HW: UK‐68,798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther 1991; 256: 318–324 [PubMed] [Google Scholar]
- 9. Knilans TK, Lathrop DA, Nanasi PP, Schwartz A, Varro A: Rate and concentration dependent effects of UK‐68,798, a potent new class III antiarrhythmic on canine Purkinje fibre action potential duration and Vmax. Br J Pharmacol 1991; 103: 1568–1572 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Rasmussen HS, Allen MJ, Blackburn KJ, Butrous GS, Dalrymple HW: Dofetilide, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 1992; 20: S96–S105 [PubMed] [Google Scholar]
- 11. Sedgwick ML, Rasmussen HS, Cobbe SM: Clinical and electrophysiological effects of intravenous dofetilide (UK‐68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am J Cardiol 1992; 69: 513–517 [DOI] [PubMed] [Google Scholar]
- 12. Echt DS, Lee JT, Murray KT, Vorperian V, Borganelli SM, Crawford DM, Friedrich T, Roden DM: A randomized, double‐blind, placebo‐controlled, dose‐ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophysiol 1995; 6: 687–699 [DOI] [PubMed] [Google Scholar]
- 13. Conelly DT, Thomsen PEB, Camm AJ, Morgan JM, Jordaens L, Butrous GS: Efficacy and safety of dofetilide, a novel class III antiarrhythmic agent, in atrioventricular nodal reentrant tachycardia (abstr). Eur Heart J 1992; 13: 304 1597215 [Google Scholar]
- 14. Wong CKY, Heald S, Thomsen PEB, Jordaens L, Conelly DT, Rasmussen HS: Electrophysiology, safety and efficacy of dofetilide in patients with atrioventricular reentrant tachycardia (AVRT) (abstr). Eur Heart J 1992; 13: 211 [Google Scholar]
- 15. Kannel WB, Plehn JF, Cupples LA: Cardiac failure and sudden death in the Framingham study. Am Heart J 1988; 115: 869–875 [DOI] [PubMed] [Google Scholar]
- 16. The SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302 [DOI] [PubMed] [Google Scholar]
- 17. Køber L, Torp‐Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbæk J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ, The TRACE Study Group : A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–1676 [DOI] [PubMed] [Google Scholar]
- 18. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Guddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–677 [DOI] [PubMed] [Google Scholar]
- 19. Beming J, Rokkedal‐Nielsen J, Launbjerg J, Fogh J, Mickley H, Andersen PE: Rapid estimation of left ventricular ejection fraction in acute myocardial infarction by echocardiographic wall motion analysis. Cardiology 1992; 80: 257–266 [DOI] [PubMed] [Google Scholar]
- 20. Køber L, Torp‐Pedersen C, Carlsen J, Videbæk R, Egeblad H, on behalf of the TRACE Study Group : An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multicentre studies as used in the TRACE study. Eur Heart J 1994; 15: 1616–1620 [DOI] [PubMed] [Google Scholar]
- 21. Lachin JM: Introduction to sample size determination and power analysis for clinical trials. Cont Clin Trial 1981; 2: 93–113 [DOI] [PubMed] [Google Scholar]
- 22. Greene HL, Richardson DW, Barker AH, Roden DM, Capone RJ, Echt DS, Friedman LM, Gillespie MJ, Hallstrom AP, Verter J: Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989; 63: 1–6 [DOI] [PubMed] [Google Scholar]
- 23. Fananapazir L, Cropp A: Dofetilide (UK 68,798) prevents ventricular tachycardia on Holter and inducible sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy (abstr). J Am Coll Cardiol 1992; 19: 224A [Google Scholar]
- 24. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, Silverman NH, Tajik AJ: Recommendations for quantitation of the left ventricle by two‐dimensional echocardiography. J Am Soc Echocardiogr 1989; 2: 358–367 [DOI] [PubMed] [Google Scholar]
- 25. Berning J, Steensgaard‐Hansen F: Early estimation of risk by echocardiographic determination of wall motion index in an unselected population with acute myocardial infarction. Am J Cardiol 1990; 65: 567–576 [DOI] [PubMed] [Google Scholar]